Browsing: Bispecific

Dr. Binod Dhakal and Dr. Prerna Mewawalla discuss how evolving dosing strategies are helping improve the real-world use of BCMA-directed…

Dr. Binod Dhakal, Dr. Carol Ann Huff, and Dr. Prerna Mewawalla discuss the growing number of BCMA-directed bispecific antibody options…

Description – Dr. Ajai Chari and Dr. Rahul Banerjee discuss the increasingly complex treatment sequencing decisions facing clinicians in relapsed/refractory…

Bispecific antibodies and CAR T-cell therapy have both become effective treatment options for patients with relapsed/refractory follicular lymphoma, prompting ongoing…

CancerNetwork® spoke with Megan Melody, MD, MS, a malignant hematologist specializing in lymphoma and cellular therapy and clinical director of…

Sequencing bispecific antibodies and CAR T-cell therapy in multiple myeloma and lymphoma was among the unresolved questions discussed at the…

Choosing the optimal third-line therapeutic strategy for relapsed/refractory follicular lymphoma remains a complex clinical decision, as highlighted in a recent…

Dr. Binod Dhakal, Dr. Prerna Mewawalla, and Dr. Carol Ann Huff discuss practical strategies for managing the safety profile of…

Dr. Binod Dhakal leads a discussion on patient selection for BCMA-directed bispecific antibodies in relapsed/refractory multiple myeloma (RRMM), focusing on…

Transitioning into a discussion of emerging clinical evidence, Dr. Binod Dhakal and Dr. Prerna Mewawalla examine the efficacy endpoints that…